Free Press Journal
  • Sensex falls 188 points on global cues, weak macro data

    Mumbai: Benchmark Sensex tumbled over 188 points to close at 37,663.56 today, tracking weak global cues on concerns over Turkey’s financial crisis amid sustained foreign fund outflows.

  • Sensex rebounds 200 pts as July F&O series opens strong

    Mumbai: Reversing a two-session slide, the benchmark BSE Sensex rose over 200 points and the Nifty reclaimed the 10,600-mark in early trade today on fresh buying by investors as the July derivatives contracts started on a strong note amid recovery in the rupee.

  • BSE Sensex

    Sensex gains 147 pts on firm global cues, Nifty reclaims 10,600

    Mumbai: The benchmark BSE Sensex rose 147 points and Nifty reclaimed 10,600 mark in early trade today on sustained buying by domestic institutional investors amid firm Asian cues. Encouraging earnings by blue-chip company also added to the uptrend. The 30-share index rose 147.25 points, or 0.42 per cent, to 34,598.02. The gauge had gained 35.19 points in the previous session. The NSE Nifty was up 23.90 points, or 0.22 per cent, to 10,608.60.

  • BSE Sensex off to flying start in Muhurat trading; climbs 154 pts

    Mumbai : Market benchmark BSE Sensex rose by over 154 points to trade above the 28,000-mark on sustained buying by participants in the opening trade of a special Muhurat session to mark the start of Hindu Samvat Year 2073, reports PTI. The Sensex surged by 154.20 points, or 0.55 per cent, to reach 28,095.71 in the first five minutes of trade.

  • Sun Pharma completes divestment of 7 brands

    New Delhi : Drug major Sun Pharmaceutical Industries completed the divestment of its seven prescription brands in India to RPG Life Sciences. This has been done after receiving approval of the Competition Commission of India and completion of all the necessary formalities for closure of the transaction, Sun Pharmaceutical Industries said in a filing to BSE. On July 27, 2016 Sun Pharma had informed the bourses that it had signed an agreement with

  • Sun Pharma in $50 million deal with Spanish firm

    Chennai: Indian drug major Sun Pharmaceutical Industries Ltd said it entered into $50 million licensing agreement with Spanish firm Almirall for the development and commercialisation of tildrakizumab for psoriasis in Europe.

  • SPARC and Sun Pharma ink licensing pact for epilepsy drug

    New Delhi: Sun Pharma Advanced Research Company (SPARC) and its parent Sun Pharma have entered into a licensing arrangement for its Elepsia tablets, used in the treatment of epilepsy, in the US market for an up-front payment of USD 10 million.

  • Sun Pharma to buy back shares at Rs 900/share

    New Delhi:  Sun Pharma said it will buy back shares worth Rs 675 crore at Rs 900 a piece on proportionate basis. “The buyback is being undertaken to return surplus funds to the equity shareholders and thereby, enhancing the overall returns to shareholders,” Sun Pharma said.

  • Sensex surges 232 points

    Mumbai  : RBI’s decision to remain accommodative propelled market to an over 7-month high as the Sensex wrested back control of the crucial 27,000-mark at the close by surging more than 232 points. Banking and realty stocks fired on all cylinders while global cues were positive.

  • Markets end flat, log 2nd consecutive weekly gains

    Mumbai :  Markets ended steady in a choppy session on Friday with the Sensex falling below the 27,000-mark after marking its new 7-month high in intra-day trade following profit-booking in recent outperformers, even as both indices recorded gains for the second straight week.

  • Nifty ends above 8150, Sensex flat; Sun Pharma, Reliance down

    New Delhi: The market on Tuesday ended after a lot of struggle as the Sensex closed down 57.64 points or 0.2 percent at 26667.96, and the Nifty ended 18.40 points or 0.2 percent at 8160.10. Tata Motors, Tata Steel, SBI, Maruti and Adani Ports were top gainers while Sun Pharma, TCS, GAIL, ONGC and Reliance were losers in the Sensex.

  • Sensex, Nifty open with gains; SBI top gainer

    New Delhi: The market on Monday opened strong supported by index heavyweights. The Sensex moved up 111.59 points or 0.4 percent at 26765.19, and the Nifty traded up 35 points or 0.4 percent at 8191.65.

  • Sun Pharma acquires 14 drug brands from Novartis in Japan

    Chennai: In a $293 million cash deal India’s Sun Pharmaceutical Industries Ltd. has agreed to buy 14 established prescription brands from Novartis AG and Novartis Pharma AG in Japan, the Indian company said.

  • NSE Nifty

    Sensex, Nifty open flat; Sun Pharma gains

    Mumbai : The market has opened flat on Tuesday. The Sensex is up 1.03 points at 25736.93 and the Nifty is down 4.80 points at 7829.65.

  • Ranbaxy integration: Sun may drop some non-strategic units

    New Delhi : Sun Pharma may discontinue certain non-strategic businesses as part of its integration process with Ranbaxy Laboratories, which it acquired in a USD 4 billion deal last year.

  • Sensex down

    Sensex down for 5th day, slips 181 pts to trade near 1-mth low

    Mumbai: The domestic stock market extended loses to a fifth straight session today as the benchmark BSE Sensex slipped by 181 points to fall to a one-month low of 26,656.83 bogged down by weaker-than-expected quarterly numbers of heavyweights, ITC and L&T.

  • Sun Pharma in race to acquire InSite Vision?

    New Delhi : Drug major Sun Pharmaceutical Industries is said to be in race to acquire US-based eye care firm InSite Vision Inc at a price of USD 0.35 per share. “InSite’s Board of Directors has determined that the previously announced unsolicited offer from a global pharmaceutical company to acquire all outstanding shares of InSite Vision common stock at USD 0.35 per share in an all- cash transaction constitutes a ‘Company Superior

  • Sun Pharma Q4 profit at Rs 888 cr

    New Delhi :  Sun Pharmaceutical Industries today posted a consolidated net profit of Rs 888.05 crore for the fourth quarter ended March 31, mainly due to Ranbaxy merger impact and price erosion in some products in the US.